Asset Details
Do you wish to reserve the book?
Digitoxin — A Reminder for Digoxin
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Digitoxin — A Reminder for Digoxin
Do you wish to request the book?
Digitoxin — A Reminder for Digoxin
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Digitoxin — A Reminder for Digoxin
2025
Overview
Cardiac glycosides are among the oldest medications in cardiovascular care, prized for their actions as positive inotropic agents and modulators of atrioventricular conduction. In heart failure with reduced ejection fraction, their mechanistic rationale was so convincing that digitalis became a mainstay of treatment long before the initiation of large-scale trials investigating the effects of cardiac glycosides on morbidity and mortality. Early mechanistic and hemodynamic studies of cardiac glycosides, together with trials that showed improved exercise capacity and quality of life, reinforced their use. This evidence was bolstered by randomized withdrawal trials, in which discontinuation of digoxin led to rapid clinical . . .
Publisher
Massachusetts Medical Society
